Key result
Magnesium sulfate infusion reduced cardiac biomarkers, ECG changes, and the incidence of postoperative myocardial infarction in patients with concentric left ventricular hypertrophy undergoing cardiac surgery.
Why the study?
To assess the cardioprotective effect of magnesium sulfate in patients with left ventricular concentric hypertrophy undergoing cardiac surgery.
Does perioperative magnesium sulfate infusion reduce myocardial injury and improve hemodynamics in patients with concentric left ventricular hypertrophy undergoing cardiac surgery?
RCT (n=250)
Double-blind
Random numbers generated through Excel
No
Does perioperative magnesium sulfate infusion reduce myocardial injury and improve hemodynamics in patients with concentric left ventricular hypertrophy undergoing cardiac surgery?
Perioperative magnesium sulfate infusion provides cardioprotection by reducing myocardial injury biomarkers and the need for hemodynamic support in patients with concentric left ventricular hypertrophy undergoing cardiac surgery.
Answers are grounded in this paper and cite their sources.
Magnesium infusion reduced myocardial injury markers and support needs in LVH cardiac surgery patients; extends perioperative cardioprotection evidence to this high-risk group.
Objective: The objective of this study was to assess the cardioprotective effect of magnesium sulfate in patients with left ventricular concentric hypertrophy undergoing cardiac surgery. Design: The study was a double-blinded randomized study. Setting: This study was conducted at a cardiac center. Patients: The study included 250 patients. Intervention: The study included two groups (each = 125): Group M - the patients who received magnesium sulfate infusion (15 mg/kg/h). The infusion was started 20 min before induction, during surgery, and the first postoperative 24 h. Group C - the patients who received an equal amount of normal saline. Measurements: The variables included troponin I level, creatinine kinase-MB (CK-MB) level, electrocardiograph (ECG) with automatic ST-segment analysis (leads II and V), E/A peak ratio, end-diastolic volume, cardiac index (CI), heart rate, mean arterial blood pressure (MAP), mean arterial pulmonary pressure (mPAP), pulmonary and systemic vascular resistances, and pharmacological and mechanical support. Main Results: The troponin I level, CK-MB, and ECG changes were lower in Group M than Group C (P < 0.05). The E/A peak ratio and end-diastolic volume increased in Group M than Group C (P < 0.05). There was a significant increase in the CI and a decrease in the heart rate, mPAP, pulmonary vascular resistances, and pharmacological and mechanical support in Group M compared to Group C (P < 0.05). There were minimal changes in the MAP and systemic vascular resistance in Group M compared to Group C (P < 0.05). Conclusion: The magnesium sulfate provides a cardioprotective effect in patients with concentric ventricular hypertrophy undergoing cardiac surgery. It decreases the incidence of perioperative myocardial infarction and arrhythmia. Furthermore, it decreases the requirement of pharmacological and mechanical support.
No takes yet. Share an insight, caveat, or question.
Soliman et al. (2019) conducted an RCT in Concentric left ventricular hypertrophy undergoing cardiac surgery (n=250). Magnesium sulfate vs. Normal saline was evaluated on Myocardial protective effect (assessed by serum troponin I, CK-MB, arrhythmia, ECG changes, new regional wall motion abnormalities, and diastolic dysfunction) (p=<0.05). Magnesium sulfate infusion reduced cardiac biomarkers, ECG changes, and the incidence of postoperative myocardial infarction in patients with concentric left ventricular hypertrophy undergoing cardiac surgery.
Synapse has enriched 10 related papers. Consider them for comparative context: